Alessia Pochesci
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 17, 2021
Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy.
Journal: Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
Published: May 11, 2020
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: April 07, 2020
EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 23, 2019
Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients.
Journal: Drugs of today (Barcelona, Spain : 1998)
Published: November 10, 2017
Lung Tissue Injury as an Atypical Response to Nivolumab in Non-Small Cell Lung Cancer.
Journal: American journal of respiratory and critical care medicine
Published: September 15, 2017
Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment.
Journal: Pharmacological research
Published: December 11, 2016
Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice.
Journal: OncoTargets and therapy
Published: November 02, 2016
Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data.
Journal: Expert review of clinical pharmacology
Published: September 15, 2016
Immunotherapy in non-small cell lung cancer: evolution of knowledge and clinical advances
Journal: Recenti progressi in medicina
Published: April 20, 2016
Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?
Journal: Journal of thoracic disease
Published: April 15, 2016
Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancer.
Journal: Anti-cancer agents in medicinal chemistry
Published: July 26, 2012
Showing 1-12 of 12
Last Updated: 09/26/2026